Showing results (51-60 of 70) with videos related to
Sort By:
Pageof 7
BMC Cancer|October 3, 2022
Liquid biopsy for detecting epidermal growth factor receptor mutation among patients with non-small cell lung cancer treated with afatinib: a multicenter prospective studyHiroaki Fujii, Hideyuki Nagakura, Nobuaki Kobayashi, et al.Frontiers in Oncology|November 19, 2024
Total baseline tumor size predicts survival among patients with advanced small-cell lung cancer receiving chemotherapy plus programmed death-ligand 1 inhibitor as first-line therapy: a multicenter retrospective observational studyAnna Tanaka, Shuhei Teranishi, Yukihito Kajita, et al.Translational Lung Cancer Research|August 13, 2025
Real-world efficacy of immune checkpoint inhibitors in PD-L1 negative non-small cell lung cancer: a multicenter retrospective studySuguru Muraoka, Nobuaki Kobayashi, Ayami Kaneko, et al.Cancers|November 14, 2023
Tailoring Therapeutic Strategies in Non-Small-Cell Lung Cancer: The Role of Genetic Mutations and Programmed Death Ligand-1 Expression in Survival OutcomesNobuaki Kobayashi, Kenji Miura, Ayami Kaneko, et al.Thoracic Cancer|December 6, 2021
Pembrolizumab monotherapy versus pembrolizumab plus chemotherapy in patients with non-small-cell lung cancer: A multicenter retrospective trialHiromi Matsumoto, Nobuaki Kobayashi, Kohei Somekawa, et al.Nihon Kokyuki Gakkai Zasshi = the Journal of the Japanese Respiratory Society|March 6, 2009
[A case of lymphocytic interstitial pneumonia complicated with primary Sjögren's syndrome followed by chest CT scanning for thirteen years]Jun Tsukiji, Takeshi Kaneko, Masako Inoue, et al.Thoracic Cancer|April 11, 2024
Real-world evidence of efficacy of pembrolizumab plus chemotherapy and nivolumab plus ipilimumab plus chemotherapy as initial treatment for advanced non-small cell lung cancerAyami Kaneko, Nobuaki Kobayashi, Kenji Miura, et al.Therapeutic Advances in Medical Oncology|August 4, 2022
Prospective analysis of factors precluding the initiation of durvalumab from an interim analysis of a phase II trial of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small cell lung cancer in Japan (SAMURAI study)Shigeru Tanzawa, Tomonori Makiguchi, Sadatomo Tasaka, et al.Therapeutic Advances in Medical Oncology|December 26, 2022
A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study): primary analysisHisashi Tanaka, Shigeru Tanzawa, Toshihiro Misumi, et al.Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy|May 15, 2020
Clinical course of 2019 novel coronavirus disease (COVID-19) in individuals present during the outbreak on the Diamond Princess cruise shipHideaki Kato, Hiroyuki Shimizu, Yasushi Shibue, et al.Pageof 7